NVUS vs. PHIO, LGVN, PHAS, NBY, REVB, ARDS, BCEL, ARAV, CWBR, and BPTS
Should you be buying Novus Therapeutics stock or one of its competitors? The main competitors of Novus Therapeutics include Phio Pharmaceuticals (PHIO), Longeveron (LGVN), PhaseBio Pharmaceuticals (PHAS), NovaBay Pharmaceuticals (NBY), Revelation Biosciences (REVB), Aridis Pharmaceuticals (ARDS), Atreca (BCEL), Aravive (ARAV), CohBar (CWBR), and Biophytis (BPTS). These companies are all part of the "medical" sector.
Novus Therapeutics (NASDAQ:NVUS) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.
57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 2.2% of Novus Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Novus Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Phio Pharmaceuticals had 12 more articles in the media than Novus Therapeutics. MarketBeat recorded 12 mentions for Phio Pharmaceuticals and 0 mentions for Novus Therapeutics. Phio Pharmaceuticals' average media sentiment score of 0.58 beat Novus Therapeutics' score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.
Novus Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
Novus Therapeutics received 216 more outperform votes than Phio Pharmaceuticals when rated by MarketBeat users. Likewise, 66.84% of users gave Novus Therapeutics an outperform vote while only 63.16% of users gave Phio Pharmaceuticals an outperform vote.
Phio Pharmaceuticals' return on equity of -123.19% beat Novus Therapeutics' return on equity.
Phio Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 412.82%. Given Phio Pharmaceuticals' higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Novus Therapeutics.
Summary
Phio Pharmaceuticals beats Novus Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Novus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Novus Therapeutics Competitors List
Related Companies and Tools
